Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Atox Bio Publishes Data Demonstrating the Broad Therapeutic Effect of AB103

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
Findings published in the Journal of Infectious Diseases.

Atox Bio has announced new data in an animal model of necrotizing soft tissue infection (NSTI), commonly known as “flesh eating bacteria” demonstrating that administration of a single dose of AB103, given several hours after infection even without any antibiotics, increased survival in animals, and reduced tissue necrosis, inflammation and bacterial burden at the site of infection without compromising the immune response.

NSTI or flesh eating bacteria is a life-threatening bacterial infection with significant morbidity and no currently approved therapies.

These finding are significant as they suggest that AB103 has a broad therapeutic window and could be used even in cases of antibiotic ineffectiveness such as with antibiotic resistant bacteria.

The data were published in a paper titled “A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft tissue infection induced by Streptococcus pyogenes” that was published in the March issue of the Journal of Infectious Diseases.

This new research supports the positive results obtained in the recently completed Phase 2a clinical trial with AB103 in 40 patients with NSTI conducted at 6 leading medical centers across the U.S.

The randomized, double-blind, placebo-controlled study demonstrated that patients treated with AB103 had a meaningful improvement across multiple endpoints in NSTI caused by different types of pathogens, including gram positive bacteria, gram negative bacteria and mixed infections.

Patients treated with AB103 had a faster resolution of organ dysfunction, spent fewer days in the intensive care unit, required fewer days of assisted ventilation and needed fewer surgical procedures to remove infected tissue.

AB103 has received an orphan drug status from the FDA in October 2011 and a fast track status in August 2012.

Alan S. Cross, M.D., Professor of Medicine at University of Maryland in Baltimore, Center for Vaccine Development, and the Paper’s lead co-author, stated, "The results with AB103 are impressive. Unlike the case with other agents assessed in animal models, AB103 is highly effective even when given several hours after infection."

Raymond Kaempfer, Ph.D., Professor of molecular biology and cancer research at the Faculty of Medicine of The Hebrew University of Jerusalem, Israel, Atox Bio’s Chief Scientist and the Paper’s second lead co-author, said, "Our insight into how an excessive inflammatory response is generated via the newly identified bottleneck of the CD28 co-stimulatory receptor, now allows for more effective treatment of live bacterial infection."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos